Skip to content

Selective Serotonin Reuptake Inhibitor Discontinuation for Psilocybin Treatment and Contributions to Alcohol Addiction Relapse

Mark A Frye, Balwinder Singh, Scott Breitinger, Tyler Oesterle

The Journal of Clinical Psychiatry August 25, 2024 DOI: 10.4088/jcp.24cr15378 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Case study Case report Peer reviewed
Sample size 1
Population A man with alcohol use disorder
Interventions SSRI naltrexone
Topics Addiction Anxiety Psilocybin Serotonin
Keywords Discontinuation Serotonin uptake inhibitors Serotonin reuptake inhibitor Hallucinogen Psychotherapist Pharmacology Fluoxetine Antidepressant Receptor
Citations 2
Key findings Discontinuing an SSRI to participate in a psilocybin ceremony may contribute to relapse in a person with AUD who had been stable on medication.

Abstract

A man with AUD achieves sobriety on treatment with an SSRI and naltrexone, but then stops taking the SSRI to participate in a psilocybin “ceremony.” What factors contributed to his subsequent relapse to alcohol use?

Comparable studies

Other case reports and case series on psilocybin for addiction, most cited first.

Study Year Design Participants
Psilocybin-assisted psychotherapy for methamphetamine dependence: a case report involving daily methamphetamine use A 36-year-old transwoman who was a daily methamphetamine user 2024 Case study n = 1
To treat or not to treat? High-potency benzodiazepine use in a case of comorbid hallucinogen persisting perception disorder and alcohol use disorder. A 37-year-old man with hallucinogen persisting perception disorder and substance use... 2022 Case study n = 1

Explore topics

By condition and practice